

### **REMARKS**

Applicant respectfully requests reconsideration. Claims 1-9, 12, and 25 were previously pending in this application. Claims 1-6 have been amended. Support for the claim amendments may be found in the specification (for example, page 3, line 1 – page 4, line 31; and the Figures). Claims 26-32 have been added. Claims 12 and 25 have been cancelled. Claims 1-9 and 26-32 remain pending with claims 1, 28 and 31 being independent. No new matter has been added.

In all instances herein where reference to the specification of the instant application is made, references is made to the corresponding published PCT application (International Patent Publication WO 04/026850); copy enclosed.

#### **Objections to the Claims**

Claim 12 was objected to as being of improper dependent form for failing to further limit the subject matter of the previous claim. Without acceding to the merits of the rejection, Applicant has cancelled claim 12.

Therefore, withdrawal of the objection based on this ground is respectfully requested.

#### **Rejection of Claims 2, 3, and 12 under 35 U.S.C. §112, second paragraph**

Claims 2, 3, and 12 were rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention. Without acceding to the merits of the rejection, Applicant has amended claims 2-3 and has cancelled claim 12.

Therefore, withdrawal of the objection based on this ground is respectfully requested.

#### **Rejection of Claims 1-9, 12, and 25 under 35 U.S.C. §112, first paragraph**

Claims 1-9, 12, and 25 were rejected under 35 U.S.C. §112, first paragraph, because, according to the Patent Office, the specification does not enable any person skilled in the art to which it pertains, or with which it is most closely connected, to make the invention commensurate in scope with these claims. Applicant respectfully disagrees.

Applicant notes that the Patent Office must consider not just a single factor, but a totality of the circumstances involving many factors when making a determination that the application is not enabled. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). Applicant submits that an analysis of the *Wands* factors weighs in favor of Applicant's assertion of enablement over the full scope of the claims, as discussed in detail below.

#### Breadth of the Claims

The breadth of the claims is reasonable in view of the teaching in the specification, as described further below in view of the other *Wands* factors. It is noted that the claims are not so broad as to encompass processes for preparing 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles including any functional group(s). Instead, the claims include significant structural limitation. The claimed system must be a 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole having a structure as indicated in structure 5a and substituted with one or more of the groups listed in claim 1. While claim 1 covers a process for preparing a variety of compounds and is not limited to the preparation of one, specific compound, those of ordinary skill in the art would easily be able to select, without undue experimentation, suitable starting materials for use in the context of the invention to prepare a particular desired compound.

#### The Nature of the Invention

The nature of the invention is a process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles that may be substituted with a variety of functional groups. As noted above, those of ordinary skill in the art would be able to select suitable starting materials for use in the invention, to prepare a particular desired compound without undue experimentation.

#### The State of the Prior Art

The state of the prior art is advanced. Various starting materials which are capable of being used in the context of the present invention to obtain a particular, desired product, are well-known to those of ordinary skill in the art, as described in the specification and in references of record in this application (please see page 11, lines 12-18 of the specification). Further, the design and synthesis of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles using a wide variety of starting material is aided by knowledge in the art related to the compatibility of various functional groups with processes as described in the present invention. For example, with the benefit of the present

specification, those of ordinary skill in the art would expect the functional groups listed in claim 1 to generally be compatible with (e.g., inert to) the reaction conditions utilized in the process of claim 1.

#### The Level of Ordinary Skill in the Art

The level of ordinary skill in the art is high. The relevant art is synthetic organic chemistry, and the skilled artisan is generally familiar with methods for synthesizing a wide variety of compounds, such as 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles by, with the benefit of the present specification, varying the starting materials used in a synthetic process, such as a process of claim 1.

#### The Level of Predictability of the Art

With respect to starting materials which are suitable for use in the process described in claim 1, and with the benefit of the present specification, the predictability of the art is reasonably high. Those of ordinary skill in the art would be able to select, using the teachings of the specification, appropriate starting materials for use in the present invention to obtain a particular, desired product with a high level of predictability. For example, those of ordinary skill in the art would be able to select a protected cyclohexanedione starting material, an amine starting material, or a thiourea starting material, each having one or more functional groups, to produce a desired 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole as described in the present invention, wherein the functional group(s) are substantially inert to reaction conditions used in processes of the invention.

#### The Amount of Direction Provided

The amount of direction provided by the Applicant in the specification is substantial. Applicant provides, in the working examples and in the specification, techniques that are applicable to various starting materials in the synthesis of substituted 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles. Those of ordinary skill in the art would be able to readily select and/or prepare starting materials, including numerous commercially available starting materials, that may be used in the claimed process, using the teachings of the specification. For example, the specification includes examples of a wide range of starting materials and reagents suitable for use in the present invention (page 5, line 18 – page 7, line 10; and the Figures).

#### The Existence of Working Examples

Applicant has provided three working examples demonstrating synthesis of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles using the teachings in the specification. The methods described in the examples are not only applicable to the specific compounds described, but many of these methods may be applied to synthesize a variety of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles without any level of undue experimentation. For example, the examples teach the synthesis of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles containing alkyl groups, which those of ordinary skill in the art would be able to modify using routine experimentation by the use of different starting materials, i.e., other substituted protected cyclohexanediones, substituted amines, and substituted thioureas.

#### The Quantity of Experimentation Needed

The amount of experimentation required to practice within the scope of the claims that stand rejected on this ground, in view of the totality of teachings of the specification of this application and the state of the art, is routine experimentation. Starting materials which may be used to form 4,5,6,7-tetrahydro-6-aminobenzothiazoles, in general, are readily available, and one of ordinary skill in the art can determine which starting materials, or combination of starting materials, would be suitable for use in the present invention without undue experimentation. Screening for such compounds, if not quickly identified in other ways, would be routine. A survey of the prior art (references included in the specification and of record in the present application) provides evidence of the fact that such starting materials in general are known to those skilled in the art.

Therefore, a full and fair analysis of the *Wands* factors strongly suggests that the Applicant has enabled the claimed invention throughout its full scope.

Accordingly, withdrawal of the rejection under 35 U.S.C. §112, first paragraph, is respectfully requested.

#### Rejection of Claims 1-9, 12, and 25 under 35 U.S.C. §103(a)

Claims 1-9, 12, and 25 were rejected under 35 U.S.C. §103(a) as being unpatentable over European Patent No. EP 0207696A1 ("Leguzza") in view of Solomons et al., Organic Chemistry 2008, 9<sup>th</sup> Edition, John Wiley & Sons, Inc., page 224-236 ("Solomons"). Specifically, the Office Action states that, because Solomons teaches that iodine is a better leaving group than bromine, it

would have been obvious to one of ordinary skill in the art at the time that the invention was made to substitute iodine for bromine in the process of Leguzza, to obtain the process recited in claim 1. Applicant respectfully traverses the rejection.

As an initial matter, Applicant disagrees with the assertion by the Patent Office that the alpha-bromoketone formed in Leguzza is not isolated. Leguzza clearly states that bromine and hydrobromide are “removed *in vacuo* to leave a brown viscous oil comprising 2-bromo-4-di-n-propylaminocyclohexanone,” (page 13, lines 20-23, of Leguzza) indicating that the alpha-bromoketone formed in Leguzza, while not fully purified or characterized, is isolated.

Applicant sees no motivation or suggestion in Leguzza or Solomons to combine the teachings of Leguzza and Solomons in the manner stated in the Office Action. By contrast, those of ordinary skill in the art would expect that the use of iodine in the Leguzza process would produce an alpha-iodoketone that is highly unstable, relative to the corresponding alpha-bromoketone. Those of ordinary skill in the art would also expect that the alpha-haloketone intermediate could not be isolated. Thus, there would be no reasonable expectation of success in modifying the process of Leguzza with the teaching of Solomons.

Furthermore, Applicant notes that, in determining the differences between the prior art and the claimed invention, Patent Office has not considered whether the claimed invention as a whole would have been obvious. In addition to the use of bromine and hydrobromide to form an alpha-bromoketone, Leguzza differs from the present invention in that the process disclosed in Leguzza involves the separate steps of (1) forming an isolated alpha-bromoketone and (2) subsequently adding thiourea to the isolated alpha-bromoketone, to form the product. Applicant also notes that, in the Leguzza process, the alpha-bromoketone is formed in the presence of volatile reagents including bromine, hydrobromic acid, and acetic acid. By contrast, the process recited in claim 1 does not require the isolation of the alpha-haloketone intermediate and does not employ the use of bromine, hydrobromic acid, and acetic acid.

As such, Applicant sees no motivation or suggestion in Leguzza or Solomons to make any modification to Leguzza process that would result in the invention as recited in claim 1. Therefore, claim 1 is not unpatentable over Leguzza in view of Solomons for at least this reason. Claims 2-9 depend from claim 1 and, therefore, are also not unpatentable over Leguzza in view of Solomons.

Accordingly, withdrawal of the rejection of these claims is respectfully requested.

In view of the above amendment, applicant believes the pending application is in condition for allowance.

Dated: February 29, 2008

Respectfully submitted,

By 

Timothy J. Oyer, Ph.D.

Registration No.: 36,628

Karen V. Martin, Ph.D.

Registration No.: 61,652

WOLF, GREENFIELD & SACKS, P.C.

Federal Reserve Plaza

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

(617) 646-8000

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
WO 2004/026850 A1

(51) International Patent Classification<sup>7</sup>: C07D 277/82,  
317/72, C07C 225/20, A61K 31/429, A61P 25/18, 25/28

(21) International Application Number:  
PCT/GB2003/004022

(22) International Filing Date:  
17 September 2003 (17.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0221513.5 17 September 2002 (17.09.2002) GB

(71) Applicant (for all designated States except US): GENER-  
ICS [UK] LIMITED [GB/GB]; Albany Gate, Darkes  
Lane, Potters Bar, Hertfordshire EN6 1AG (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GUPTA, Ashwin,  
Kumar [IN/IN]; Type II-B 17, 99-1st Floor, Lake Side  
Gate, IIT Bombay Powai, 400 076 Mumbai (IN). AGHAV,  
Balu [IN/IN]; c/o Mr. V.N. Deshpande, B-10/1/2/3,  
Sector-13, CIDCO Colony, 410 206 New Panvel (E)  
(IN). TRIPATHI, Anil, Kumar [IN/IN]; c/o Mr. V.N.

Deshpande, B-10/1/2/3, Sector-13, CIDCO Colony, 410  
206 New Panvel (E) (IN). GAITONDE, Abhay [IN/IN];  
8, Niwara Co-op Hsg. Soc, Veer Sawarkar Path, Naupade,  
400 602 Thane (IN).

(74) Agents: ELEND, Almut, Susanne et al.; Venner, Shipley  
& Co., 20 Little Britain, London EC1A 7DH (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF 2-AMINO-4,5,6,7-TETRAHYDRO-6-AMINO BENZOTHIAZOLES FROM  
CYCLOHEXANES AND CYCLOHEXANONES AS INTERMEDIATES



a: reductive amination with R<sup>1</sup>R<sup>2</sup>NH

b: deprotection

c: (i) iodine, H<sub>2</sub>N(C=S)NHR<sup>3</sup>; (ii) OH<sup>-</sup>

(57) Abstract: The present invention relates to processes for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles (5a) from cyclohexanes (2a) and cyclohexanones (3a) as intermediate.



— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



PROCESS FOR THE PREPARATION OF 2-AMINO-4,5,6,7-TETRAHYDRO-6-AMINO BENZOTHAZOLES FROM CYCLOHEXANES AND CYCLOHEXANONES AS INTERMEDIATES


### Technical field

5 The present invention relates to processes for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles and to novel cyclohexanes and cyclohexanones for use in these processes.

### Background art

10

Certain 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles are known to have dopamine D-2 activity and are therefore potentially useful as pharmaceuticals for the treatment of psychiatric disorders such as schizophrenia and Alzheimer's disease. One such compound, the dihydrochloride salt of (S)-2-amino-4,5,6,7-  
15 tetrahydro-6-(propylamino)-benzothiazole I (pramipexole), is marketed as a pharmaceutical for the treatment of Parkinson's disease. The numbering of pramipexole I is indicated below.



20 Processes for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles are disclosed in patents US 4843086, US 4886812 and patent applications WO 02/22590 A1 and WO 02/22591 A1. A procedure to these types of compound is also disclosed by C.S. Schneider and J. Mierau in J. Med. Chem., 1987, vol. 30, pages 494-498.

25


However, known processes for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles are not satisfactory, particularly for industrial scale manufacture, as they have been found to be low yielding and involve the use of

hazardous and difficult to handle reagents such as bromine, hydrazine and potassium chromate.

### Summary of the invention


5

A first aspect of the present invention is a process for the preparation of a 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a




or a salt thereof, comprising the steps of:

- 10 (a) reductively aminating a protected cyclohexandione 1p with an amine R¹R²NH to yield a protected 4-amino-cyclohexanone 2p:



wherein P is a protected ketone functionality, and R¹ and R² are any atom or group or, together with the nitrogen to which they are attached, form a ring;

- 15 (b) deprotecting the protected 4-amino-cyclohexanone 2p to yield an unprotected 4-amino-cyclohexanone 3a



- (c) treating the unprotected 4-amino-cyclohexanone 3a with iodine and a substituted thiourea H₂N(C=S)NHR³, wherein R³ is any atom or group, to yield the  
20 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a or a salt thereof.

For the purposes of the present invention, an "alkyl" group is defined as a monovalent saturated hydrocarbon, which may be straight-chained or branched, or be or include cyclic groups. Examples of alkyl groups are methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *t*-butyl and *n*-pentyl groups. Preferably an alkyl group is straight-chained or branched and does not include any heteroatoms in its carbon skeleton. Preferably an alkyl group is a C<sub>1</sub>-C<sub>12</sub> alkyl group, which is defined as an alkyl group containing from 1 to 12 carbon atoms. More preferably an alkyl group is a C<sub>1</sub>-C<sub>6</sub> alkyl group, which is defined as an alkyl group containing from 1 to 6 carbon atoms. An "alkylene" group is similarly defined as a divalent alkyl group.

An "alkenyl" group is defined as a monovalent hydrocarbon, which comprises at least one carbon-carbon double bond, which may be straight-chained or branched, or be or include cyclic groups. Examples of alkenyl groups are vinyl, allyl, but-1-enyl and but-2-enyl groups. Preferably an alkenyl group is straight-chained or branched and does not include any heteroatoms in its carbon skeleton. Preferably an alkenyl group is a C<sub>2</sub>-C<sub>12</sub> alkenyl group, which is defined as an alkenyl group containing from 2 to 12 carbon atoms. More preferably an alkenyl group is a C<sub>2</sub>-C<sub>6</sub> alkenyl group, which is defined as an alkenyl group containing from 2 to 6 carbon atoms. An "alkenylene" group is similarly defined as a divalent alkenyl group.

An "alkynyl" group is defined as a monovalent hydrocarbon, which comprises at least one carbon-carbon triple bond, which may be straight-chained or branched, or be or include cyclic groups. Examples of alkynyl groups are ethynyl, propargyl, but-1-ynyl and but-2-ynyl groups. Preferably an alkynyl group is straight-chained or branched and does not include any heteroatoms in its carbon skeleton. Preferably an alkynyl group is a C<sub>2</sub>-C<sub>12</sub> alkynyl group, which is defined as an alkynyl group containing from 2 to 12 carbon atoms. More preferably an alkynyl group is a C<sub>2</sub>-C<sub>6</sub> alkynyl group, which is defined as an alkynyl group containing from 2 to 6 carbon atoms. An "alkynylene" group is similarly defined as a divalent alkynyl group.

An "aryl" group is defined as a monovalent aromatic hydrocarbon. Examples of aryl groups are phenyl, naphthyl, anthracenyl and phenanthrenyl groups. Preferably

an aryl group does not include any heteroatoms in its carbon skeleton. Preferably an aryl group is a C<sub>4</sub>-C<sub>14</sub> aryl group, which is defined as an aryl group containing from 4 to 14 carbon atoms. More preferably an aryl group is a C<sub>6</sub>-C<sub>10</sub> aryl group, which is defined as an aryl group containing from 6 to 10 carbon atoms. An  
5 "arylene" group is similarly defined as a divalent aryl group.

Where a combination of groups is referred to as one moiety, for example, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule. A  
10 typical example of an arylalkyl group is benzyl.

For the purposes of this invention, an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group may be substituted with one or more of -F, -Cl, -Br, -I, -CF<sub>3</sub>, -CCl<sub>3</sub>, -CBr<sub>3</sub>, -Cl<sub>3</sub>, -OH,  
15 -SH, -NH<sub>2</sub>, -CN, -NO<sub>2</sub>, -COOH, -R<sup>4</sup>-O-R<sup>5</sup>, -R<sup>4</sup>-S-R<sup>5</sup>, -R<sup>4</sup>-SO-R<sup>5</sup>, -R<sup>4</sup>-SO<sub>2</sub>-R<sup>5</sup>,  
-R<sup>4</sup>-SO<sub>2</sub>-OR<sup>5</sup>, -R<sup>4</sup>O-SO<sub>2</sub>-R<sup>5</sup>, -R<sup>4</sup>-SO<sub>2</sub>-N(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-NR<sup>5</sup>-SO<sub>2</sub>-R<sup>5</sup>, -R<sup>4</sup>O-SO<sub>2</sub>-OR<sup>5</sup>,  
-R<sup>4</sup>O-SO<sub>2</sub>-N(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-NR<sup>5</sup>-SO<sub>2</sub>-OR<sup>5</sup>, -R<sup>4</sup>-NR<sup>5</sup>-SO<sub>2</sub>-N(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-N(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-N(R<sup>5</sup>)<sub>3</sub><sup>+</sup>,  
-R<sup>4</sup>-P(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-Si(R<sup>5</sup>)<sub>3</sub>, -R<sup>4</sup>-CO-R<sup>5</sup>, -R<sup>4</sup>-CO-OR<sup>5</sup>, -R<sup>4</sup>O-CO-R<sup>5</sup>, -R<sup>4</sup>-CO-N(R<sup>5</sup>)<sub>2</sub>,  
-R<sup>4</sup>-NR<sup>5</sup>-CO-R<sup>5</sup>, -R<sup>4</sup>O-CO-OR<sup>5</sup>, -R<sup>4</sup>O-CO-N(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-NR<sup>5</sup>-CO-OR<sup>5</sup>,  
20 -R<sup>4</sup>-NR<sup>5</sup>-CO-N(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-CS-R<sup>5</sup>, -R<sup>4</sup>-CS-OR<sup>5</sup>, -R<sup>4</sup>O-CS-R<sup>5</sup>, -R<sup>4</sup>-CS-N(R<sup>5</sup>)<sub>2</sub>,  
-R<sup>4</sup>-NR<sup>5</sup>-CS-R<sup>5</sup>, -R<sup>4</sup>O-CS-OR<sup>5</sup>, -R<sup>4</sup>O-CS-N(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-NR<sup>5</sup>-CS-OR<sup>5</sup>,  
-R<sup>4</sup>-NR<sup>5</sup>-CS-N(R<sup>5</sup>)<sub>2</sub> or -R<sup>5</sup>. In this context, -R<sup>4</sup>- is independently a chemical bond, a C<sub>1</sub>-C<sub>10</sub> alkylene, C<sub>1</sub>-C<sub>10</sub> alkenylene or C<sub>1</sub>-C<sub>10</sub> alkynylene group. -R<sup>5</sup> is independently hydrogen, unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl or unsubstituted C<sub>6</sub>-C<sub>10</sub> aryl. Optional  
25 substituent(s) are not taken into account when calculating the total number of carbon atoms in the parent group substituted with the optional substituent(s).

Any optional substituent may be protected. Suitable protecting groups for protecting optional substituents are known in the art, for example from "Protective  
30 Groups in Organic Synthesis" by T.W. Greene and P.G.M. Wuts (Wiley-Interscience, 2<sup>nd</sup> edition, 1991).

For the purposes of this invention, a "salt" is any acid addition salt, preferably a pharmaceutically acceptable acid addition salt, including but not limited to a hydrohalogenic acid salt such as hydrofluoric, hydrochloric, hydrobromic and hydroiodic acid salt; an inorganic acid salt such as nitric, perchloric, sulfuric and phosphoric acid salt; an organic acid salt such as a sulfonic acid salt (for example  
5 methanesulfonic, trifluoromethanesulfonic, ethanesulfonic, isethionic, benzenesulfonic, p-toluenesulfonic or camphorsulfonic acid salt), acetic, malic, fumaric, succinic, citric, tartaric, benzoic, gluconic, lactic, mandelic, mucic, pantoic, pantothenic, oxalic and maleic acid salt; and an aminoacid salt such as ornithinic,  
10 glutamic and aspartic acid salt. The acid addition salt may be a mono- or di-acid addition salt. A preferred salt is a di-hydrohalogenic, di-sulphuric, di-phosphoric or di-organic acid salt. A most preferred salt is a di-hydrochloric acid salt.

P is a protected ketone functionality. Suitable protecting groups are commonly  
15 known in the art, for example from Chapter 4 of "Protective Groups in Organic Synthesis" by T.W. Greene and P.G.M. Wuts (Wiley-Interscience, 2<sup>nd</sup> edition, 1991).

Preferably the protected ketone functionality P is an acyclic ketal or derivative 1q, a cyclic ketal or derivative 1r, 1s or 1t, or a hydrazone or oxime 1u, as shown in Figure  
20 4. More preferably P is a cyclic ketal 1r, most preferably P is a monoethyleneketal 1, as shown in Figures 2 and 3.

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> can be any atom or group. Preferably R<sup>1</sup> and R<sup>2</sup> are not amine protecting groups. Amine protecting groups are commonly known in the art, for  
25 example from Chapter 7 of "Protective Groups in Organic Synthesis" by T.W. Greene and P.G.M. Wuts (Wiley-Interscience, 2<sup>nd</sup> edition, 1991). Most preferably one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the other of R<sup>1</sup> and R<sup>2</sup> is an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group, which may include one or more heteroatoms N, O or S in its  
30 carbon skeleton. Such an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group, which may include one or more heteroatoms N, O or S in its carbon skeleton, does not encompass carbonyl -CO-R groups, wherein R is any atom or group.

Optionally  $R^1$ ,  $R^2$  and  $R^3$  are independently hydrogen or an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group, which may include one or more heteroatoms N, O or S in its carbon skeleton.

Optionally  $R^1$ ,  $R^2$  and  $R^3$  are independently an alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group, which may include one or more heteroatoms N, O or S in its carbon skeleton, and which may be optionally substituted with one or more of -F, -Cl, -Br, -I, -CF<sub>3</sub>, -CCl<sub>3</sub>, -CBr<sub>3</sub>, -CI<sub>3</sub>, -OH, -SH, -NH<sub>2</sub>, -CN, -NO<sub>2</sub>, -COOH, -R<sup>4</sup>-O-R<sup>5</sup>, -R<sup>4</sup>-S-R<sup>5</sup>, -R<sup>4</sup>-SO-R<sup>5</sup>, -R<sup>4</sup>-SO<sub>2</sub>-R<sup>5</sup>, -R<sup>4</sup>-N(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-Si(R<sup>5</sup>)<sub>3</sub>, -R<sup>4</sup>-CO-R<sup>5</sup>, -R<sup>4</sup>-CO-OR<sup>5</sup>, -R<sup>4</sup>O-CO-R<sup>5</sup>, -R<sup>4</sup>-CO-N(R<sup>5</sup>)<sub>2</sub>, -R<sup>4</sup>-NR<sup>5</sup>-CO-R<sup>5</sup>, -R<sup>4</sup>-CS-R<sup>5</sup> or -R<sup>5</sup>, wherein

-R<sup>4</sup> is independently a chemical bond, a C<sub>1</sub>-C<sub>10</sub> alkylene, C<sub>1</sub>-C<sub>10</sub> alkenylene or C<sub>1</sub>-C<sub>10</sub> alkynylene group, and

-R<sup>5</sup> is independently hydrogen, unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl or unsubstituted C<sub>6</sub>-C<sub>10</sub> aryl.


Optionally  $R^1$ ,  $R^2$  and  $R^3$  are independently an alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group, which does not include any heteroatoms in its carbon skeleton, and which may be optionally substituted with one or more of -F, -Cl, -Br, -I, -CF<sub>3</sub>, -CCl<sub>3</sub>, -CBr<sub>3</sub>, -CI<sub>3</sub>, -OH, -SH, -NH<sub>2</sub>, -CN, -NO<sub>2</sub>, -COOH, -OR<sup>5</sup>, -SR<sup>5</sup>, -SO-R<sup>5</sup>, -SO<sub>2</sub>-R<sup>5</sup>, -N(R<sup>5</sup>)<sub>2</sub>, -Si(R<sup>5</sup>)<sub>3</sub>, -CO-R<sup>5</sup>, -CO-OR<sup>5</sup>, -O-CO-R<sup>5</sup>, -CO-N(R<sup>5</sup>)<sub>2</sub>, -NR<sup>5</sup>-CO-R<sup>5</sup>, -CS-R<sup>5</sup> or -R<sup>5</sup>, wherein

-R<sup>5</sup> is independently hydrogen, unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl or unsubstituted C<sub>6</sub>-C<sub>10</sub> aryl.

Preferably  $R^1$ ,  $R^2$  and  $R^3$  are independently hydrogen or an unsubstituted alkyl, aryl or heteroaryl group, which does not include any heteroatoms N, O or S in its carbon skeleton. More preferably,  $R^1$ ,  $R^2$  and  $R^3$  are independently hydrogen or an unsubstituted C<sub>1-10</sub> alkyl group. More preferably,  $R^1$ ,  $R^2$  and  $R^3$  are independently hydrogen or an unsubstituted C<sub>1-6</sub> alkyl group. More preferably, one of  $R^1$  and  $R^2$  is hydrogen and the other of  $R^1$  and  $R^2$  is an unsubstituted C<sub>1-6</sub> alkyl group, and  $R^3$  is


hydrogen. Most preferably, one of  $R^1$  and  $R^2$  is hydrogen and the other of  $R^1$  and  $R^2$  is *n*-propyl, and  $R^3$  is hydrogen.

Alternatively,  $R^1$  and  $R^2$  can, together with the nitrogen to which they are attached, form a ring. Optionally  $-NR^1R^2$  together form an optionally substituted heterocycloalkyl, heterocycloalkenyl or heteroaryl ring. Optionally  $-NR^1R^2$  together form




10 Preferably the reductive amination of step (a) is carried out with  $NaCNBH_3$ .

A second aspect of the present invention is a 4-amino-cyclohexanone-ethyleneketal 2a or a 4-amino-cyclohexanone 3a



15 for use in a process of the first aspect of the present invention.  $R^1$  and  $R^2$  are as defined above with reference to the first aspect of the present invention. Preferably one of  $R^1$  and  $R^2$  is hydrogen and the other of  $R^1$  and  $R^2$  is *n*-propyl.

A third aspect of the present invention is a 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a



or a salt thereof, obtained by a process of the first aspect of the present invention.  $R^1$ ,  $R^2$  and  $R^3$  are as defined above with reference to the first aspect of the present

invention. Preferably one of  $R^1$  and  $R^2$  is hydrogen and the other of  $R^1$  and  $R^2$  is *n*-propyl, and  $R^3$  is hydrogen. Preferably the compound is a di-hydrochloric acid salt.

5 The 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles 5a or salts thereof have at least one chiral centre and can therefore exist in the form of various stereoisomers. The present invention embraces all of these stereoisomers and mixtures thereof. Mixtures of these stereoisomers can be resolved by conventional methods, for example, chiral chromatography, fractional recrystallisation, derivatisation to form diastereomers and subsequent resolution, and resolution using enzymes.

10

The 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a or salt thereof of the present invention preferably comprises at least 95% of the (R)- or the (S)-enantiomer, preferably at least 98% of the (R)- or the (S)-enantiomer, and more preferably at least 99% of the (R)- or the (S)-enantiomer. Generally, the (S)-  
15 enantiomer is the preferred enantiomer.

20

The 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a or salt thereof may be used as a medicament, preferably for the treatment of a psychiatric or neurological disorder such as schizophrenia, Alzheimer's disease or Parkinson's disease.

A fourth aspect of the present invention is a pharmaceutical composition, comprising 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a or salt thereof and a pharmaceutically acceptable carrier or diluent. Preferably the pharmaceutical composition is suitable for the treatment of a psychiatric or neurological disorder  
25 such as schizophrenia, Alzheimer's disease or Parkinson's disease.

30

A fifth aspect of the present invention is a method of treating a psychiatric or neurological disorder such as schizophrenia, Alzheimer's disease or Parkinson's disease, comprising administering a therapeutically effective amount of a 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a or a salt thereof to a subject in need of such treatment.



### Brief description of the drawings

Figure 1 is a schematic illustration of the process of the present invention.

Figures 2 and 3 are schematic illustrations of preferred processes of the present invention.

Figure 4 illustrates preferred protected ketone functionalities P.


### Detailed description of the invention

10 The inventors have found that processes for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles 5a are greatly improved by the process outlined in Figure 1, wherein R<sup>1</sup> and R<sup>2</sup> can be any atom or group or, together with the nitrogen to which they are attached, form a ring, and wherein R<sup>3</sup> can be any atom or group. R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are preferably hydrogen or an unsubstituted alkyl, aryl or  
15 heteroaryl group.

The process outlined in Figure 1 is short, utilises a readily available starting material, a protected cyclohexandione 1p, and does not require any hazardous chemical reagents. Each step of the process is high yielding and affords products of very  
20 high purity.

Therefore a first aspect of the current invention is a process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles 5a by the process specified in Figure 1.

25 It has been disclosed in prior art documents WO 02/22590 and WO 02/22591 that, in practice, compounds of formula 5a, comprising a primary amino or a secondary alkylamino group, cannot be prepared directly from the corresponding ketones 3a. The process shown in Figure 1, however, illustrates that the process of the current invention does indeed allow a compound 5a to be prepared from ketones 3a directly  
30 without the requirement of preparing and isolating an  $\alpha$ -haloketone of formula 4, where X is a halide such as chloride or bromide, or the requirement of a protecting group on the nitrogen atom of the amine substituent -NR<sup>1</sup>R<sup>2</sup> of the ketone 3a.



Therefore, in a preferred embodiment of the present invention, the  $\alpha$ -haloketone of formula 4 is not isolated. Moreover, in a preferred embodiment of the present invention, the nitrogen atom of the amine substituent  $-NR^1R^2$  of the ketone 3a is not protected.

In a preferred embodiment of the first aspect of the invention, cyclohexandione is protected as a cyclohexandione monoethyleneketal 1, as shown in Figures 2 and 3.

10

A further preferred embodiment of the first aspect of the invention is a process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-(propylamino)-benzothiazole 5, as outlined in Figure 3.


15 The process outlined in Figure 3 can readily be adapted to afford pramipexole I or its salts, for example by resolution of compound 5. Methods for resolving enantiomers are well known in the art and include, for example, chiral chromatography, fractional recrystallisation, derivatisation to form diastereomers and subsequent resolution, and resolution using enzymes.

20


A further aspect of the invention is therefore pramipexole I and its salts, when prepared by a process according to the current invention.

Further aspects of the invention include novel compounds of the formula 2a or 3a, wherein  $R^1$  and  $R^2$  are as defined above, which are useful intermediates in the synthesis of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles 5a.

25



Preferred embodiments of these aspects are compounds 2 and 3, as shown in Figure 3.



5

The process outlined in Figure 3 is an example of a procedure comprising the process of the current invention and detailed procedures for this process are found in the experimental section. Compounds of the current invention are also exemplified in Figure 3 and in the experimental section.

10

The process of the present invention is short, utilises readily available starting materials and does not involve the use of hazardous or difficult to handle reagents such as bromine, hydrazine or potassium chromate. Each step of the process of the present invention is high yielding and affords products of very high purity. Thus the process is easy to scale up for industrial scale manufacturing. Optionally 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles 5a and salts thereof may be manufactured in batches of 5kg or more, or even 10kg or more.

15

## 20 Experimental procedure

### 4-*n*-Propylamino-cyclohexanone-ethyleneketal 2

A mixture of *n*-propyl amine (162ml, 1.474mol) in methanol (500ml) was chilled to 0-5°C. To this solution was added methanolic hydrochloric acid (155ml, 44.47%) dropwise over a period of 30 minutes to achieve a pH of 6-7. Cyclohexandione monoethyleneketal 1 (100g, 0.641mol) was charged at 5°C and the reaction was stirred for 15 minutes. Sodium cyanoborohydride (60g, 0.952mol) was added in 15 minutes at 5°C. The pH increased to about 8 and methanolic hydrochloric acid (15ml, 44.47%) was added to bring the pH to 6-7. The reaction was allowed to come to 24-26°C. Stirring was continued for 2 hours. Methanol was distilled off (450ml). Sodium carbonate (95g, 0.896mol) was dissolved in water (850ml) and charged to the reaction mass at ambient temperature in one shot. The reaction mass was extracted with dichloromethane (2500ml). The dichloromethane layers were combined and dried over sodium sulfate (8.5g). The dichloromethane layer was concentrated to dryness at 40°C and 15mbar pressure. The product 2 was light yellow viscous oil. The weight of the product 2 obtained was 135g (105.8%); GC purity 97.74%.

<sup>1</sup>H NMR (δ ppm): 0.9-1.0 (t, 3H, CH<sub>3</sub> of *n*Pr); 1.5-1.7 (m, 7H, CH<sub>2</sub>CH<sub>3</sub> of *n*Pr and 5H of cyclohexyl ring); 1.75-1.85 (m, 2H, 2H of cyclohexyl ring); 1.95-2.05 (m, 1H, 1H of cyclohexyl ring); 2.75 (t, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 3.75-3.85 (m, 1H, NHCH); 3.9 (s, 2H, CH<sub>2</sub> of ethylene ketal) and 4.0 (s, 2H, CH<sub>2</sub> of ethylene ketal).  
<sup>13</sup>C NMR (δ ppm): 11.7 (CH<sub>3</sub> of *n*Pr); 21.8 (CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 28.5 (C-3 and C-5); 33.1 (C-2 and C-6); 48.3 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 55.8 (C-4); 64.5 (C of ethylene ketal); 64.6 (C of ethylene ketal); 108.1 (C-1).

### 25 4-*n*-Propylamino-cyclohexanone 3

4-*N*-propylamino-cyclohexanone-ethyleneketal 2 (134g, 0.673mol) was taken in tetrahydrofuran (268ml) and cooled to 4-6°C. Concentrated hydrochloric acid (178ml, 2.01mol) was diluted with water (2144ml) and the mixture was cooled to 4°C. This diluted hydrochloric acid was added to the reaction mixture at 4-6°C in 15 minutes. The reaction was allowed to come to 24-26°C and stirring was continued for 24 hours. The reaction mass (2750ml) was concentrated to 1800ml at 50°C and 35mbar pressure. Sodium carbonate (148g, 1.4mol) was added to achieve

pH 10. The reaction mixture was extracted with dichloromethane (3670ml). The dichloromethane layers were combined and dried over sodium sulfate (20g). The dichloromethane layer was concentrated to dryness at 40°C and 15mbar pressure. The product 3 was yellow viscous oil. The weight of the product 3 obtained was  
5 52.5g (52.84%); GC purity 86.07%.

<sup>1</sup>H NMR (δ ppm): 0.9-1.0 (t, 3H, CH<sub>3</sub> of *n*Pr); (m, 2H, CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 1.6-1.75 (m, 2H, 2H of cyclohexyl ring); 2.05-2.15 (m, 2H, 2H of cyclohexyl ring); 2.2-2.3 (m, 2H, 2H of cyclohexyl ring); 2.4-2.55 (m, 2H, 2H of cyclohexyl ring); 2.55-2.65 (t,  
10 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 2.9-3.0 (m, 1H, NHCH).  
<sup>13</sup>C NMR (δ ppm): 12.3 (CH<sub>3</sub> of *n*Pr); 24.0 (CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 32.6 (C-3 and C-5); 39.1 (C-2 and C-6); 50.0 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 54.4 (C-4); 211.9 (C-1).

2-Amino-6-*n*-propylamino-5,6,7,8-tetrahydrobenzthiazole 5

15

4-*n*-Propylamino-cyclohexanone 3 (5g, 32.26mmol) was charged in absolute ethanol (50ml) at 24-26°C. Iodine (8.5g, 33.5mmol) was added to it under stirring followed by thiourea (5g, 65.7mmol) at 24-26°C. The reaction mass was refluxed for 32 hours. Heating was stopped and the reaction mass was allowed to cool to 24-26°C.  
20 It was maintained at that temperature for 20 hours. 2-Amino-6-*n*-propylamino-5,6,7,8-tetrahydrobenzthiazole dihydroiodide salt crystallized out of the solution. Ethanol (30ml) was distilled out on the rotavapor at 50°C and 100mbar. Acetone (50ml) was added and the solid was filtered. The solid was dried at 40°C and 15mbar. The weight of the product obtained was 8.5g (56%); HPLC purity 94.97%.

25

<sup>1</sup>H NMR (δ ppm): 0.9-1.0 (t, 3H, CH<sub>3</sub> of *n*Pr) 1.6-1.8 (m, 2H, CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 2.0 (m, 1H, H-7a); 2.35 (m, 1H, H-7b); 2.7 (m, 3H, H-5a, H-8a, H-8b); 3.1 (m, 3H, H-5b and CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 3.7 (m, 1H, NHCH).  
<sup>13</sup>C NMR (δ ppm): 12.0 (CH<sub>3</sub> of *n*Pr); 21.0 (CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 22.2 (C-7); 25.5 and  
30 26.8 (C-5 and C-8); 48.7 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 54.7 (C-6); 113.0 (C-4); 134 (C-9); 171.2 (C-2).

Mass Spec: M<sup>+</sup> 211 (expected 211).

The 2-amino-6-*n*-propylamino-5,6,7,8-tetrahydrobenzthiazole dihydroiodide salt formed above (50g, 107.1mmol) was dissolved in water (200ml). The solution was cooled to 4°C and solid sodium hydroxide (50g, 1.25mol) was added in 15 minutes. The reaction was stirred for 1 hour at 24-26°C and the solid that precipitated out  
5 was filtered and dried at 40°C and 15mbar. The weight of the product 5 obtained was 17.07g (75.5%); HPLC purity 99.88%.

<sup>1</sup>H NMR (8 ppm): 0.9-1.0 (t, 3H, CH<sub>3</sub> of *n*Pr); 1.5-1.6 (m, 2H, CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 2.1 (m, 1H, H-7a); 2.3 (m, 1H, H-7b); 2.5-2.6 (m, 5H, H-5a, H-5b, H-8a, H-8b and  
10 CHCH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 2.9 (m, 2H, H-6 and CHCH<sub>2</sub>CH<sub>3</sub> of *n*Pr).

<sup>13</sup>C NMR (8 ppm): 12.0 (CH<sub>3</sub> of *n*Pr); 24.6 (CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 26.6 (C-7); 30.7 and 30.9 (C-5 and C-8); 50.7 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> of *n*Pr); 56.2 (C-6); 116.0 (C-4); 145 (C-9); 170.4 (C-2).

Mass Spec: M<sup>+</sup> 211 (expected 211).


15

It will be understood that the present invention has been described above by way of example only. The examples are not intended to limit the scope of the invention. Various modifications and embodiments can be made without departing from the scope of the invention, which is defined by the following claims.

20

## Claims


1. A process for the preparation of a 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a




5

or a salt thereof, comprising the steps of:

- (a) reductively aminating a protected cyclohexandione 1p with an amine  $R^1R^2NH$  to yield a protected 4-amino-cyclohexanone 2p:



- 10 wherein P is a protected ketone functionality, and  $R^1$  and  $R^2$  are any atom or group or, together with the nitrogen to which they are attached, form a ring;
- (b) deprotecting the protected 4-amino-cyclohexanone 2p to yield an unprotected 4-amino-cyclohexanone 3a




- 15 (c) treating the unprotected 4-amino-cyclohexanone 3a with iodine and a substituted thiourea  $H_2N(C=S)NHR^3$ , wherein  $R^3$  is any atom or group, to yield the 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a or a salt thereof.

2. A process as claimed in claim 1, wherein P is a cyclic ketal 1r.

20


3. A process as claimed in claim 2, wherein P is a monoethyleneketal 1.
4. A process as claimed in any preceding claim, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently hydrogen or an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group, which may include one or more heteroatoms N, O or S in its carbon skeleton.
5. A process as claimed in any preceding claim, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently hydrogen or an unsubstituted alkyl, aryl or heteroaryl group, which does not include any heteroatoms N, O or S in its carbon skeleton.
6. A process as claimed in any preceding claim, wherein one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the other of R<sup>1</sup> and R<sup>2</sup> is an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group, which may include one or more heteroatoms N, O or S in its carbon skeleton.
7. A process as claimed in claim 6, wherein one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the other of R<sup>1</sup> and R<sup>2</sup> is *n*-propyl.
8. A process as claimed in any preceding claim, wherein R<sup>3</sup> is hydrogen.
9. A process as claimed in any preceding claim, wherein the reductive amination of step (a) is carried out with NaCNBH<sub>3</sub>.
10. A 4-amino-cyclohexanone-ethyleneketal 2a



for use in a process as claimed in any one of claims 1 to 9.



11. A 4-amino-cyclohexanone 3a



for use in a process as claimed in any one of claims 1 to 9.

- 5 12. A compound as claimed in claim 10 or claim 11, wherein one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the other of R<sup>1</sup> and R<sup>2</sup> is *n*-propyl.
13. A 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a or a salt thereof, obtained by a process as claimed in any one of claims 1 to 9.
- 10 14. A compound as claimed in claim 13, wherein one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the other of R<sup>1</sup> and R<sup>2</sup> is *n*-propyl, and wherein R<sup>3</sup> is hydrogen.
- 15 15. A compound as claimed in claim 13 or claim 14, wherein the compound is a di-hydrochloric acid salt.
16. A compound as claimed in any one of claims 13 to 15, comprising at least 95% of the (R)- or the (S)-enantiomer.
- 20 17. A compound as claimed in any one of claims 13 to 16 for use as a medicament.
18. A compound as claimed in claim 17, wherein the medicament is suitable for the treatment of a psychiatric or neurological disorder.
- 25 19. A compound as claimed in claim 18, wherein the psychiatric or neurological disorder is schizophrenia, Alzheimer's disease or Parkinson's disease.

20. A pharmaceutical composition, comprising a compound as claimed in any one of claims 13 to 19 and a pharmaceutically acceptable carrier or diluent.

21. A pharmaceutical composition as claimed in claim 20, suitable for the  
5 treatment of a psychiatric or neurological disorder.

22. A pharmaceutical composition as claimed in claim 21, wherein the psychiatric or neurological disorder is schizophrenia, Alzheimer's disease or Parkinson's disease.


10

23. A method of treating a psychiatric or neurological disorder, comprising administering a therapeutically effective amount of a 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole 5a or a salt thereof as claimed in any one of claims 13 to 19 to a subject in need of such treatment.

15

24. A method as claimed in claim 23, wherein the psychiatric or neurological disorder is schizophrenia, Alzheimer's disease or Parkinson's disease.

20




a: reductive amination with R<sup>1</sup>R<sup>2</sup>NH

b: deprotection

c: (i) iodine, H<sub>2</sub>N(C=S)NHR<sup>3</sup>; (ii) OH<sup>-</sup>

Figure 1




a: reductive amination with  $R^1R^2NH$

b: deprotection

c: (i) iodine,  $H_2N(C=S)NHR^3$ ; (ii)  $OH^-$

Figure 2



a: *n*-propylamine, NaCNBH<sub>3</sub>, MeOH/HCl

b: aq. HCl/THF

c: (i) iodine, H<sub>2</sub>N(C=S)NH<sub>2</sub>, ethanol, reflux; (ii) aq. NaOH

Figure 3








Figure 4

# INTERNATIONAL SEARCH REPORT

Internat Application No  
PCT/GB 03/04022

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C07D277/82 C07D317/72 C07C225/20 A61K31/429 A61P25/18 A61P25/28		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D C07C		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 207 696 A (LILLY CO ELI) 7 January 1987 (1987-01-07) page 7, line 16 -page 9, line 2; claims 1-6	10,11,13
A	page 7, line 16 -page 11, line 4 page 16, line 10 -page 18, line 15 claims 1-12	1-24
X	WO 02 22590 A (POSPISILIK KAREL; LEMMENS JACOBUS MARIA (NL); SYNTHON B V (NL); HO) 21 March 2002 (2002-03-21) claims 9-18,20-22	13-16
A	page 19, line 5 -page 2, line 17; claims 9-18,20-22	1-24
	--- -/--	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search  10 February 2004		Date of mailing of the international search report  18/02/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 851 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Hass, C

## INTERNATIONAL SEARCH REPORT

Inte

Application No

PCT/GB 03/04022

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 731 374 A (KOBINGER WALTER ET AL) 15 March 1988 (1988-03-15) cited in the application column 16, line 63 -column 17, line 3; claims	13,14, 17-24
A	column 3, line 34 -column 4, line 26 & US 4 886 812 A 12 December 1989 (1989-12-12) cited in the application & US 4 843 086 A cited in the application	1
X	WO 02 22591 A (POSPISILIK KAREL; SYNTHON B V (NL)) 21 March 2002 (2002-03-21) cited in the application page 1, line 5 -page 2, line 2 page 14, line 15 - line 29 page 17, line 20 - line 25	13-24
X	WO 96 18395 A (BOEHRINGER INGELHEIM KG; ROHDE FRANK A (DE); UPJOHN CO (US); HALL) 20 June 1996 (1996-06-20) claims	13-24
X	WO 99 59563 A (GOMEZ MANCILLA BALTAZAR; UPJOHN CO (US)) 25 November 1999 (1999-11-25) page 5, line 6 - line 18	13-15, 17-24
X	DE 36 20 813 A (BOEHRINGER INGELHEIM KG) 23 December 1987 (1987-12-23) claims 1,7,8; example 1	13,15-24
X	EP 0 749 962 A (LILLY CO ELI) 27 December 1996 (1996-12-27) page 14, line 17 - line 35	10,11
A	page 14, line 17 - line 38	1
X	US 5 708 187 A (FLAUGH MICHAEL EDWARD ET AL) 13 January 1998 (1998-01-13) column 17, line 53 -column 18, line 12	10,11
A	column 17, line 53 -column 18, line 18	1
X	EP 1 008 592 A (FUJIREBIO KK) 14 June 2000 (2000-06-14) example 118	10



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-16

Process for the preparation of compound 5a, which is already known from the art, from intermediates 2a and 3a, these intermediates, and the known product 5a per se.

2. Claims: 17-24

Pharmaceutical compositions and methods making use of the known compound 5a.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 03/04022

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 23 and 24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal

Application No

PCT/GB 03/04022

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0207696	A	07-01-1987	AU 5919586 A EP 0207696 A1 JP 62000473 A ZA 8604626 A	08-01-1987 07-01-1987 06-01-1987 24-02-1988
WO 0222590	A	21-03-2002	ES 2187249 A1 AU 1105502 A AU 1281502 A EP 1318986 A1 WO 0222590 A1 WO 0222591 A1 US 2002103240 A1	16-05-2003 26-03-2002 26-03-2002 18-06-2003 21-03-2002 21-03-2002 01-08-2002
US 4731374	A	15-03-1988	DE 3447075 A1 DE 3508947 A1 AT 45735 T AU 583874 B2 AU 5154485 A BG 62023 B2 BR 1100678 A3 CA 1263653 A1 CS 9104099 A3 DD 242230 A5 DE 3572485 D1 DK 590285 A EP 0186087 A1 ES 8702787 A1 ES 8707513 A1 ES 8707514 A1 ES 8707515 A1 FI 855102 A ,B, GR 853126 A1 HK 78692 A HU 39736 A2 IE 58863 B1 IL 77415 A JP 1854941 C JP 5072907 B JP 61155377 A KR 9309791 B1 LU 90208 A9 MX 9202792 A1 NO 855195 A ,B, NZ 214661 A PH 24533 A PT 81735 A ,B SG 82492 G US 4843086 A US 4886812 A ZA 8509731 A	03-07-1986 18-09-1986 15-09-1989 11-05-1989 17-07-1986 30-12-1998 13-10-1999 05-12-1989 16-09-1992 21-01-1987 28-09-1989 23-06-1986 02-07-1986 01-04-1987 16-10-1987 16-10-1987 16-10-1987 23-06-1986 22-04-1986 23-10-1992 29-10-1986 17-11-1993 19-03-1990 07-07-1994 13-10-1993 15-07-1986 11-10-1993 06-04-1998 30-06-1992 23-06-1986 26-04-1990 03-08-1990 01-01-1986 04-12-1992 27-06-1989 12-12-1989 26-08-1987
WO 0222591	A	21-03-2002	ES 2187249 A1 AU 1105502 A AU 1281502 A EP 1318986 A1 WO 0222590 A1 WO 0222591 A1 US 2002103240 A1	16-05-2003 26-03-2002 26-03-2002 18-06-2003 21-03-2002 21-03-2002 01-08-2002

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No  
PCT/GB 03/04022

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9618395	A	20-06-1996	US 5650420 A	22-07-1997
			AT 238790 T	15-05-2003
			AU 712666 B2	11-11-1999
			AU 4413496 A	03-07-1996
			CA 2207323 A1	20-06-1996
			DE 69530606 D1	05-06-2003
			DK 797439 T3	25-08-2003
			EP 0797439 A1	01-10-1997
			JP 10510809 T	20-10-1998
			NZ 298606 A	23-02-2001
			SI 797439 T1	31-12-2003
			WO 9618395 A1	20-06-1996
			US 6156777 A	05-12-2000
			US 6458820 B1	01-10-2002
WO 9959563	A	25-11-1999	AU 748629 B2	06-06-2002
			AU 3741999 A	06-12-1999
			BR 9909917 A	26-12-2000
			CA 2327299 A1	25-11-1999
			CN 1301159 T	27-06-2001
			EP 1076559 A2	21-02-2001
			HU 0101803 A2	28-03-2002
			JP 2002515425 T	28-05-2002
			NO 20005757 A	14-11-2000
			PL 344574 A1	05-11-2001
			SK 16272000 A3	10-05-2001
			TR 200003356 T2	21-03-2001
			WO 9959563 A2	25-11-1999
			US 6503920 B1	07-01-2003
			ZA 200005847 A	19-04-2002
DE 3620813	A	23-12-1987	DE 3620813 A1	23-12-1987
			AT 70060 T	15-12-1991
			AU 593357 B2	08-02-1990
			AU 7457887 A	24-12-1987
			CA 1322372 C	21-09-1993
			CS 8704511 A3	13-05-1992
			DD 259623 A5	31-08-1988
			DE 3774942 D1	16-01-1992
			DK 168437 B1	28-03-1994
			EP 0251077 A1	07-01-1988
			ES 2040226 T3	16-10-1993
			FI 872719 A ,B,	22-12-1987
			GR 3003656 T3	16-03-1993
			HU 47091 A2	30-01-1989
			IE 60676 B1	10-08-1994
			JP 63017872 A	25-01-1988
			KR 9504000 B1	22-04-1995
			NO 872574 A ,B,	22-12-1987
			NZ 220800 A	21-12-1989
			PH 24207 A	10-04-1990
			PL 266361 A1	13-10-1988
			PT 85100 A ,B	01-07-1988
			SU 1494867 A3	15-07-1989
			US 4981862 A	01-01-1991
			ZA 8704470 A	22-02-1989
EP 0749962	A	27-12-1996	CA 2179678 A1	24-12-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern

Application No

PCT/GB 03/04022

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0749962	A	DE 69610793 D1 DE 69610793 T2 EP 0749962 A1 ES 2151993 T3	07-12-2000 03-05-2001 27-12-1996 16-01-2001
US 5708187	A	13-01-1998 US 5814653 A	29-09-1998
EP 1008592	A	14-06-2000 EP 1008592 A2 JP 2000204071 A KR 2000035402 A US 6117870 A	14-06-2000 25-07-2000 26-06-2000 12-09-2000